Building an integrated fourth-generation AI-based risk screening platform for smart digital oncology
We are fourth-generation AI designers and risk engineers building the first smart modular cancer digital clinic to capture rare events with smart prevention, risk prediction and early weak signals detection, years before they occur.
Before a rare event speaks, weak signals whisper
By transforming complex raw data, multimodal imaging and multi-physics signals into predictive weak signals, and detecting them at the earliest stages of cancer development, HOPE VALLEY AI empowers patients, healthcare providers, public health stakeholders, and clinical researchers to anticipate, assess, and predict, with integrated trustworthy risk-informed AI solutions, cancer risk and associated rare events, surfacing the earliest indicators and features, years before such events occur.
40%
of all diagnosed cancer cases are preventable and are associated with avoidable risk factors.
Source : Santé publique France, 2018
40%
of breast cancers occur in women who could have been identified as augmented-risk patients, years prior to diagnosis.
Source : Interception - Gustave Roussy
11%
5-year survival rate of pancreatic cancer all stages combined. It is expected to become the 2nd deadliest cancer in France in 2040.
Source: Prof. Louis de Mestier (AP-HP)
Early detection of cancer significantly increases the chances of survival while reducing the financial burden on healthcare systems.
Patients diagnosed at stage I benefit from substantially higher 5-year survival rates, up to 99% for breast cancer and 100% for lung cancer, compared to those diagnosed at stage IV, where survival drops to as low as 7%.
Moreover, the average cancer-related healthcare costs within one year of diagnosis escalate sharply with later-stage detection. For instance, treating prostate cancer at stage IV costs over $440,000, compared to $123,000 at stage I.
Similar patterns are seen across other cancer types, with costs multiplying two to six times between early and late-stage diagnoses. These figures underscore the critical importance of early screening and detection programs, not only for saving lives but also for ensuring more sustainable healthcare expenditure.
We focus on digital oncology starting with breast cancer
We build the first smart modular breast health digital clinic for women over 25 and their primary care providers to improve access to prevention and care, particularly in underserved communities.
Empowering patients to “Know their Normal” and help their healthcare providers, clinical researchers and healthtech industry to save lives and defeat cancer with integrated prevention, 12-month and 5-year breast cancer risk prediction and AI-assisted detection of early weak signals of rare events before they occur.
We are building the first integrated smart modular breast health digital clinic to defeat breast cancer through smart prevention, multi-year risk prediction and early detection of weak signals, years before it occurs.
Smart Breast Health e-Clinic on Smartphone (1st module)
The HOPE Application, designed for women over 25, is a breast health companion that offers science-based guidance, insights, and smart tips for regular self-checks.
It is CE Class I medical device. It does not replace medical advice or a doctor’s consultation.
Integrated AI-assisted Healthcare Platform (2nd module)
The HOPE Pro Platform, designed for healthcare providers, is an AI-assisted medical solution integrating BREASCREEN and BREASCAN medical devices, currently under evaluation.
HOPE Pro will support clinical decision-making through AI-based remote patient monitoring and 12-month & 5-year risk prediction.
Integrated AI-assisted Ultrasound RF Medical Device (3rd module)
MAMMOPE is a multimodal AI-powered medical device based on a patented Ultrasound RF technology, currently in active R&D, designed to support frontline primary care providers in underserved areas.
It complements, but does not replace, the gold standard breast cancer mammography screening program.
